8-K: Ginkgo Bioworks Announces Restructuring and Revised 2024 Guidance Amidst Revenue Decline

Ginkgo Bioworks is implementing a restructuring plan, including significant workforce reductions and facility consolidation, to achieve adjusted EBITDA breakeven by the end of 2026, following a 53% revenue decrease in Q1 2024.

Summary

• Ginkgo Bioworks reported a 53% decrease in total revenue for the first quarter of 2024, falling to $38 million from $81 million in the same period last year, primarily due to the expected wind-down of K-12 testing in its Biosecurity segment.
• Cell Engineering revenue also declined by 18% to $28 million, driven by a decrease in revenue from early-stage customers, partially offset by growth from larger clients.
• The company's Biosecurity revenue was $10 million with a gross profit margin of 8%, reflecting the early stages of a transition to a more recurring business model.
• Ginkgo reported a loss from operations of $(178) million, which includes $42 million in stock-based compensation expense, compared to a loss of $(216) million in the prior year period, which included $75 million in stock-based compensation.
• Adjusted EBITDA remained flat year-over-year at $(100) million, as reduced operating expenses offset the revenue decline.
• The company plans to reduce annualized run-rate operating expenditures by $200 million by mid-2025, with a substantial portion of the reduction occurring in 2024.
• This cost reduction will be achieved through a reduction in labor expenses of at least 25% and a consolidation of facilities, including the opening of Biofab1 in mid-2025.
• Ginkgo has revised its full-year 2024 revenue guidance to $170-$190 million, with Cell Engineering services revenue expected to be $120-$140 million and Biosecurity revenue expected to be at least $50 million.
• The company aims to achieve adjusted EBITDA breakeven by the end of 2026.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is taking steps to improve its financial position through cost reductions and strategic changes, the significant revenue decline and restructuring efforts indicate substantial challenges. The long timeline to achieve EBITDA breakeven and the risks associated with the restructuring contribute to a negative sentiment.

Positives

• Ginkgo is taking decisive action to reduce costs and improve efficiency.
• The company is consolidating its operations into core facilities, which is expected to reduce expenses.
• Ginkgo is simplifying its customer programs and transaction terms to drive revenue.
• The company is expanding its partnership with Novo Nordisk.
• Ginkgo is introducing new products like Lab Data as a Service (LDaaS) and biosecurity offerings.
• Ginkgo has a strong cash balance of $840 million and no bank debt.
• The company is targeting adjusted EBITDA breakeven by the end of 2026.
• Ginkgo is seeing growth in large/enterprise customers in its Cell Engineering business.
• The company is gaining traction on an international scale in its Biosecurity business.
• Ginkgo received a grant from the Bill & Melinda Gates Foundation for measles outbreak forecasting.

Negatives

• Ginkgo experienced a significant 53% decrease in total revenue in Q1 2024.
• Cell Engineering revenue decreased by 18% in Q1 2024.
• The company reported a loss from operations of $(178) million in Q1 2024.
• Ginkgo is planning a reduction in labor expenses of at least 25%, indicating significant job losses.
• The company has revised its full-year 2024 revenue guidance downwards.
• The company is facing uncertainty regarding the timing of technical milestones.
• The company is experiencing a weaker than expected revenue ramp during the year.
• The company is transitioning its Biosecurity business to a more recurring model, which is in its early stages.

Risks

• The company's ability to realize cost savings from site consolidation is uncertain.
• There is a risk of volatility in the price of the company's securities.
• The company faces risks related to implementing business plans and realizing additional opportunities.
• There is a risk of downturns in demand for products using synthetic biology.
• The demand for passive monitoring programs and biosecurity services is uncertain.
• Changes in the biosecurity industry could impact the company.
• The company faces potential legal proceedings.
• The success of the Foundry platform programs is not guaranteed.
• The company's ability to develop engineered cells and other deliverables is uncertain.
• The product development and commercialization success of customers is a risk.
• The planned reduction in force could negatively impact the business.
• The company's ability to terminate leases or find sub-lease tenants for unused facilities is uncertain.

Future Outlook

Ginkgo aims to achieve adjusted EBITDA breakeven by the end of 2026, supported by cost reductions, operational efficiencies, and new service offerings. The company expects to add at least 100 new customer projects in 2024, including traditional Cell Programs and new offerings like Lab Data as a Service.

Management Comments

• Jason Kelly, co-founder and CEO of Ginkgo, stated that he is disappointed in the Q1 revenues and that this trend needs to change.
• Jason Kelly also mentioned that the company is simplifying both what they sell to customers and how they do the work that drives revenue.
• Jason Kelly noted that the company is consolidating its Foundry operations into Biofab1, which is expected to open in mid-2025.
• Management stated that they are simplifying transaction terms as the benefits of IP and downstream value terms were not worth the cost of slowing commercial activity.

Industry Context

The announcement reflects a broader trend in the biotech industry where companies are focusing on cost efficiency and profitability. Ginkgo's move to consolidate operations and reduce workforce is similar to actions taken by other companies facing revenue challenges. The company's focus on biosecurity and AI-driven data services aligns with growing market demands in these areas.

Comparison to Industry Standards

• Ginkgo's revenue decline of 53% in Q1 2024 is significantly worse than many of its peers in the synthetic biology space, which have generally shown more stable or growing revenues.
• Companies like Amyris and Zymergen, which have faced financial difficulties, have also undertaken restructuring efforts, but Ginkgo's scale and cash position provide a stronger foundation for recovery.
• Ginkgo's focus on biosecurity is a differentiator, but the 8% gross profit margin in this segment is low compared to established biosecurity companies.
• The target of achieving adjusted EBITDA breakeven by the end of 2026 is a common goal for growth-stage biotech companies, but the timeline is longer than some investors might expect.
• The planned 25% reduction in labor expenses is a significant move, comparable to other companies undergoing major restructuring, but it also indicates the severity of the financial challenges.

Stakeholder Impact

• Shareholders will be impacted by the significant revenue decline and restructuring efforts, potentially leading to stock price volatility.
• Employees will be impacted by the planned reduction in force, resulting in job losses.
• Customers may experience changes in service offerings and transaction terms.
• Suppliers may be affected by the company's cost reduction initiatives.
• Creditors may be concerned about the company's financial performance and restructuring.

Next Steps

• Ginkgo will consolidate its Foundry operations into a smaller number of core facilities, including Biofab1.
• The company will implement a reduction in labor expenses of at least 25%.
• Ginkgo will simplify and standardize customer programs on the Foundry platform.
• The company will launch Lab Data as a Service and modular offerings.
• Ginkgo will continue to develop and expand its biosecurity products and services.
• The company will provide further details on the restructuring plan by amendment to this Current Report on Form 8-K.
• Ginkgo will host a webcast to discuss its plan to achieve adjusted EBITDA breakeven.

Key Dates

Keywords

synthetic biology, cell programming, biosecurity, genomics, foundry, EBITDA, restructuring, cost reduction, revenue, biotech, lab automation, AI, data services